×
About 1,188 results

ALLMedicine™ Lymphangioleiomyomatosis Center

Research & Reviews  412 results

Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
https://clinicaltrials.gov/ct2/show/NCT02156115

Jun 24th, 2022 - Disorders of lymphatic function are associated with multiple presentations, the most common of which is lymphedema, a chronic swelling of the extremities, due to impaired lymphatic drainage. It can cause disability and a predisposition to infectio...

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
https://clinicaltrials.gov/ct2/show/NCT01799538

Jun 24th, 2022 - We have reported that approximately one third of patients with lymphangioleiomyomatosis (LAM) who have airflow obstruction respond to bronchodilators such as albuterol, a Beta2-adenergic receptor agonist, with an increase in forced expiratory flow...

Discovery of Sirolimus Sensitive Biomarkers in Blood
https://clinicaltrials.gov/ct2/show/NCT03304678

Jun 24th, 2022 - Sirolimus (rapamycin), which acts as a targeted inhibitor of the protein mechanistic target of rapamycin (mTOR), has been shown to be effective in patients with lymphangioleiomyomatosis (LAM). It stabilizes lung function, resolves chylous effusion...

Study of the Disease Process of Lymphangioleiomyomatosis
https://clinicaltrials.gov/ct2/show/NCT00001465

Jun 24th, 2022 - Individuals with pulmonary lymphangioleiomyomatosis develop severe destructive lung disease. Most of them are females of childbearing age. Currently, there is no proven effective therapy and the prognosis is variable. This study is designed to (a)...

see more →

Guidelines  2 results

The ERS guidelines for LAM: trying a rationale approach to a rare disease.
https://doi.org/10.1016/j.rmed.2010.03.015
Respiratory Medicine; Johnson SR

May 11th, 2010 - Lymphangioleiomyomatosis (LAM) is a rare lung disease which predominantly affects young women. LAM is associated with much morbidity and can lead to respiratory failure and death unless lung transplantation is performed. There are no randomised tr...

European Respiratory Society guidelines for the diagnosis and management of lymphangiol...
https://doi.org/10.1183/09031936.00076209
The European Respiratory Journal; Johnson SR, Cordier JF et. al.

Jan 2nd, 2010 - European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.|2010|Johnson SR,Cordier JF,Lazor R,Cottin V,Costabel U,|complications,diagnosis,therapy,

see more →

Clinicaltrials.gov  39 results

Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
https://clinicaltrials.gov/ct2/show/NCT02156115

Jun 24th, 2022 - Disorders of lymphatic function are associated with multiple presentations, the most common of which is lymphedema, a chronic swelling of the extremities, due to impaired lymphatic drainage. It can cause disability and a predisposition to infectio...

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
https://clinicaltrials.gov/ct2/show/NCT01799538

Jun 24th, 2022 - We have reported that approximately one third of patients with lymphangioleiomyomatosis (LAM) who have airflow obstruction respond to bronchodilators such as albuterol, a Beta2-adenergic receptor agonist, with an increase in forced expiratory flow...

Discovery of Sirolimus Sensitive Biomarkers in Blood
https://clinicaltrials.gov/ct2/show/NCT03304678

Jun 24th, 2022 - Sirolimus (rapamycin), which acts as a targeted inhibitor of the protein mechanistic target of rapamycin (mTOR), has been shown to be effective in patients with lymphangioleiomyomatosis (LAM). It stabilizes lung function, resolves chylous effusion...

Study of the Disease Process of Lymphangioleiomyomatosis
https://clinicaltrials.gov/ct2/show/NCT00001465

Jun 24th, 2022 - Individuals with pulmonary lymphangioleiomyomatosis develop severe destructive lung disease. Most of them are females of childbearing age. Currently, there is no proven effective therapy and the prognosis is variable. This study is designed to (a)...

Lymphangioleiomyomatosis, a Study on Cathepsin K
https://clinicaltrials.gov/ct2/show/NCT05323370

May 18th, 2022 - This is a physiopathological case-control, non-interventional, monocentric study of adult patients with lymphangioleiomyomatosis. The controls are patients followed in neurology at the CHU of Tours for a tuberous sclerosis complex without lymphang...

see more →

News  20 results

What is your diagnosis? - April 2019
https://www.mdedge.com/gihepnews/article/197796/what-your-diagnosis-april-2019?channel=27662
Sarah Melloul, MD, Mostafa El Hajjam, MD et. al.

Mar 29th, 2019 - Cystic and calcified PEComa of the ligamentum teres PEComas are tumors derived from epithelioid perivascular cells that typically coexpress smooth muscle and melanocytic markers. The family of PEComas includes angiomyolipoma, clear cell “sugar” tu.

What is the diagnosis?
https://www.mdedge.com/gihepnews/article/197796/what-diagnosis
Sarah Melloul, MD, Mostafa El Hajjam, MD et. al.

Mar 29th, 2019 - Cystic and calcified PEComa of the ligamentum teres PEComas are tumors derived from epithelioid perivascular cells that typically coexpress smooth muscle and melanocytic markers. The family of PEComas includes angiomyolipoma, clear cell “sugar” tu.

What is your diagnosis? - April 2019
https://www.mdedge.com/gihepnews/article/197796/what-your-diagnosis-april-2019
Sarah Melloul, MD, Mostafa El Hajjam, MD et. al.

Mar 29th, 2019 - Cystic and calcified PEComa of the ligamentum teres PEComas are tumors derived from epithelioid perivascular cells that typically coexpress smooth muscle and melanocytic markers. The family of PEComas includes angiomyolipoma, clear cell “sugar” tu.

This Month in the Journal CHEST® Editor’s Picks
https://www.mdedge.com/chestphysician/article/158052/society-news/month-journal-chestr-editors-picks
Richard S. Irwin, MD, FCCP, MDedge News

Feb 6th, 2018 - Giants In Chest Medicine Professor Nan-shan Zhong, MD. By Wei-jie Guan.

A 20-Year-Old Woman With Flank Pain and Vomiting
https://reference.medscape.com/viewarticle/877714_5

Mar 28th, 2017 - In 2012, new criteria for the diagnosis of TSC were published by the International Tuberous Sclerosis Complex Consensus Conference.[13] They include the following 11 major and six minor features. The major features are as follows: Hypomelanotic ma...

see more →

Patient Education  2 results see all →